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Abstract. 
 
It is well established that mutations in the 
presenilin 1 and 2 genes cause the majority of early on-
set Alzheimer’s disease (AD). However, our under-
standing of the cellular functions of the proteins they 
encode remains rudimentary. Knowledge of proteins 
with which the presenilins interact should lead to a bet-
ter understanding of presenilin function in normal and 
disease states. We report here the identiﬁcation of a cal-
cium-binding protein, calmyrin, that interacts preferen-
tially with presenilin 2 (PS2). Calmyrin is myristoy-
lated, membrane-associated, and colocalizes with PS2 
when the two proteins are overexpressed in HeLa cells. 
Yeast two-hybrid liquid assays, afﬁnity chromatogra-
phy, and coimmunoprecipitation experiments conﬁrm 
binding between PS2 and calmyrin. Functionally, 
calmyrin and PS2 increase cell death when cotrans-
fected into HeLa cells. These results allude to several 
provocative possibilities for a dynamic role of calmyrin 
in signaling, cell death, and AD.
Key words: presenilins • Alzheimer’s disease • cal-
cium-binding protein • myristoylation • cell death
 
A
 
LZHEIMER
 
’
 
S
 
 disease (AD)
 
1
 
 is a degenerative disorder
characterized clinically by progressive dementia
and neuropathologically by the presence of senile
plaques and neurofibrillary tangles (NFT). Genetic studies
indicate the etiology of AD to be heterogeneous. Muta-
tions in (amyloid precursor protein (
 
b
 
APP), presenilin
1(PS1), and presenilin 2 (PS2) (reviewed by Hardy, 1997;
Cruts and Van Broeckhoven, 1998) are linked to autoso-
mal dominant inheritance of early onset familial AD (i.e.,
FAD before 65 years of age). Many other genes, including
some that act as modifiers or risk factors, appear to be as-
sociated with late-onset AD (
 
.
 
65 yr; Corder et al., 1993;
 
Payami et al., 1997; Pericak-Vance et al., 1997; Blacker et al.,
1998; Montoya et al., 1998). Approximately 50% of all
FAD cases are linked to the presenilin genes where mis-
sense mutations are generally found in residues that are
conserved between the two proteins with the rare excep-
tions of in-frame splice deletions and premature trunca-
tions. The mechanisms by which mutations in PS and
 
b
 
APP genes cause AD are not known, although mutations
 
in these genes appear somehow interconnected as they
increase amyloidogenic A
 
b 
 
fragment accumulation (re-
viewed by Hardy, 1997).
Human PS1 and PS2 genes are both ubiquitously ex-
pressed, but at low protein levels which have lead to dif-
ficulties and inconsistencies in their detection and local-
ization. Upon overexpression, the presenilins have been
localized to the ER and nuclear envelope (see Kovacs et al.,
1996; Janicki and Monteiro, 1997 and references therein)
with one group reporting evidence also for cell surface lo-
calization (Dewji and Singer, 1997). Endogenous PS1 and
PS2 proteins, in turn, have been localized to a variety of
structures, including the ER, vesicular structures of the so-
matodentritic compartment, within axons, at centrosomes
and centromeres, and at the plasma membrane (Busciglio
et al., 1997; Capell et al., 1997; Li et al., 1997; Ye and For-
tini, 1998).
Human PS1 and PS2 proteins are 67% identical, shar-
ing highest similarity in their COOH-terminal sequence
and in multiple internal regions that are structurally pre-
dicted to form transmembrane domains (TMD). Assum-
ing the presenilins are transmembrane proteins, their to-
pography according to most models is of a protein that
 
weaves through membranes eight times with the NH
 
2
 
-
and COOH-terminal domains and the large “loop” span-
ning the putative sixth and seventh TMD all facing the cy-
toplasm (see Fig. 1; Hardy, 1997).
Several lines of evidence from a variety of species have
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Abbreviations used in this paper: 
 
AD, Alzheimer’s disease; FAD, famil-
ial AD; MTN, multiple tissue Northern; NF-L, neurofilament light; NFT,
neurofibrillary tangles; PS, presenilin; TMD, transmembrane domains. 
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indicated presenilins play important roles during develop-
ment. First, the 
 
Caenorhabditis elegans
 
 presenilin ho-
mologue, 
 
sel-12
 
, facilitates Notch-based cell signaling of
lin-12, a gene involved in cell fate determination and vulva
development (see Levitan and Greenwald, 1995). Second,
PS1 knockout mice die shortly after birth with the em-
bryos displaying central nervous system defects and ab-
normal patterning of the axial skeleton and spinal ganglia
(Shen et al., 1997; Wong et al., 1997). Third, disruption of
the 
 
Drosophila
 
 PS gene is lethal, causing Notch processing
defects as well as Notch-like phenotypes (Strul and Green-
wald, 1999; Ye et al., 1999). Although these results clearly
allude to a role for presenilins in development, the mecha-
nisms by which FAD mutations in presenilin genes cause
AD are unknown. Interestingly, mice disrupted of PS1 can
be rescued by human transgenes containing FAD-linked
PS mutations, indicating that the FAD mutations do not
affect PS functions related to embryo development in
mammals (Davis et al., 1998; Qian et al., 1998). In contrast,
the
 
 C
 
.
 
 elegans sel-12
 
 mutant is more able to discriminate
between wild-type and FAD bearing PS transgenes, being
functionally rescued by expression of wild-type human
presenilins but only partially by presenilins containing
FAD mutations (Levitan et al., 1996; Baumeister et al.,
1997). The FAD-linked PS mutations are thought to con-
fer some unknown detrimental gain of function which cor-
relates with altered 
 
b
 
APP processing (see Davis et al.,
1998; De Strooper et al., 1998; Qian et al., 1998).
Presenilins have also been implicated in the regulation
of programmed cell death (apoptosis). Evidence for such a
role was first shown when a cDNA fragment encoding the
103 COOH-terminal amino acids of mouse PS2, termed
ALG-3, was isolated in a screen for cDNAs that could res-
cue T cells from receptor-induced apoptosis (Vito et al.,
1996a). This rescue appears to be a consequence of the
ALG-3 fragment acting in a dominant negative fashion,
since expression of full-length PS2 leads to apoptosis (Vito
et al., 1996b). Compared with the apoptosis induced by the
overexpression of wild-type PS2 in PC12 and HeLa cells,
the FAD PS2-N141I mutation causes even higher levels of
apoptosis (Deng et al., 1996; Wolozin et al., 1996; Janicki
and Monteiro, 1997). Likewise, PS1 overexpression also
sensitizes cells to apoptosis (Guo et al., 1996, 1997; Wo-
lozin et al., 1998). The mechanisms by which presenilins
induce apoptosis are not fully understood, but perturba-
tions in calcium, oxidative stress (Guo et al., 1996; Keller et
al., 1998), destabilization of 
 
b
 
-catenin (Zhang et al., 1998),
and increased signaling by heterotrimeric GTP-binding
proteins have been implicated (Wolozin et al., 1996; Smine
et al., 1998).
To gain a better understanding of presenilin function,
we used the yeast two-hybrid system to identify proteins
with which human PS2 interacts. Using the loop region of
PS2 as bait we have isolated and characterized a recently
identified calcium-binding protein that binds preferentially
to PS2 compared with PS1 loop sequence. This protein,
calmyrin, displays several interesting properties including
myristoylation, membrane-association, and colocalization
with PS2 in cotransfected cells. Like presenilin, calmyrin
causes cell death when overexpressed in HeLa cells, and
interestingly, coexpression of PS2 and calmyrin promotes
an additive increase in cell death. The interaction of this
 
calcium-binding protein with PS2 may therefore be impor-
tant in presenilin function.
 
Materials and Methods
 
Primer List
 
B3
 
9
 
: 5
 
9
 
GCTGAGTACGCTCGAGGTAGGGGAGCTGGAGGGC3
 
9
 
; B5
 
9
 
:
5
 
9
 
CGCTTCTGGAATTCCCCAAAGGGCCTCTGAG3
 
9
 
; C3
 
9
 
: 5
 
9
 
GCTA-
GCATCGCTCGAGCCACACCATGGCAGATG3
 
9
 
; D5
 
9
 
: 5
 
9
 
CGCTTC-
TGGAATT\CCCCACGGTTGGCATG3
 
9
 
; E3
 
9
 
: 5
 
9
 
TATCGCTTAAGT-
CGACGATGTAGAGCTGATGGG3
 
9
 
; E5
 
9
 
: 5
 
9
 
CGGTACGTGAATTC-
AAGAAGGCGCTGCC3
 
9
 
; F3
 
9
 
: 5
 
9
 
GCTAGCATCGCTCGAGATAC-
TTGGAATTTTTGG3
 
9
 
; F5
 
9
 
: 5
 
9
 
CGTCATCAGCGAATTCCCGAAA-
GGTCCACTTCG3
 
9
 
; G3
 
9
 
: 5
 
9
 
CTCGCCTAGCCTCGAGCCACACCA-
TTGTTGAGG3
 
9
 
; L3
 
9
 
: 5
 
9
 
TCGTGAGGATCCTCGAGCTACTGGAG-
CCGCGACAGGC3
 
9
 
; L5
 
9
 
: 5
 
9
 
CTAGACCTGAATTCCCAATGGCGA-
CTGCGACCCC3
 
9
 
; M3
 
9
 
: 5
 
9
 
CGAGTAGCATGTCGACCAGGACAAT-
CTTAAAGGA3
 
9
 
; M5
 
9
 
: 5
 
9
 
GCTACACTAGCCGCGGGAATTCGGCA-
CGAGGCG3
 
9
 
; N3
 
9
 
: 5
 
9
 
CGAGTAGCATGTCGACTCACAGGACAA-
TCTTAAA3
 
9
 
; N5
 
9
 
: 5
 
9
 
GCTACACTAGCCGCGGCCACCATGGAG-
CAAAAGCTCATTTCTGAAGAGGACTTGAATCGCGGCGGGG-
CGATGGG3
 
9
 
. Restriction enzymes sites incorporated into the primers to
aid in cloning are underlined.
 
Yeast Two-Hybrid Library Screening
 
The yeast two-hybrid screen for PS2 interacting proteins was performed
essentially as described by Golemis et al. (1996), with the necessary plas-
mids and cDNA library obtained from Dr. Roger Brent (Harvard Medical
School, Cambridge, MA). The PS2-loop bait (designated PS2-loop B, see
Fig. 1 A) was constructed by PCR amplification of the region from human
PS2 (Janicki and Monteiro, 1997) using primers B5
 
9
 
 and B3
 
9
 
. The result-
ing 150-bp PCR fragment was double digested with EcoRI and XhoI and
ligated into the corresponding sites of the pEG202 LexA fusion plasmid.
This bait construct and the LacZ reporter plasmid pSH18-34 were
cotransformed into yeast strain EGY48 which was then transformed with
 
z
 
5 
 
m
 
g of human fetal brain cDNA library in pJG4-5. 1.5
 
 3 
 
10
 
7
 
 of the re-
sulting transformants were plated on Gal/Raf/CM-ura-his-trp-leu plates to
screen for transcriptional activation of the chromosomally integrated
LEU2 reporter gene. 100 Leu
 
1
 
 yeast colonies were picked to a Glu/CM-
ura-his-trp master plate, then replica-plated to Glu/CM-ura-his-trp-leu,
Gal/Raf/CM-ura-his-trp-leu, Glu/Xgal/CM-ura-his-trp and Gal/Raf/Xgal/
CM-ura-his-trp plates to test for galactose-dependent 
 
leu2
 
 and 
 
lacZ
 
 ex-
pression. Dual expression of the reporters was displayed by 15 colonies,
from which the library plasmids were recovered in 
 
Escherichia coli
 
 strain
JBe15 and subsequently transformed back into EGY48 containing
pSH18-34 and the pEG202LexA/PS2-loop B bait or one of several nega-
tive controls to test the specificity of the interaction with PS2-loop B. The
library plasmids that produced a strong and specific interaction with PS2-
loop B were recovered in 
 
E
 
.
 
 coli
 
 strain DH1 and the DNA sequence of
their inserts was determined.
DNA and protein sequences were analyzed using MacVector 6.5 (Ox-
ford Molecular). Homology searches of the NCBI databases were per-
formed using the BLAST program. Three of seven putative interactors
were independent clonings of the same cDNA which we named calmyrin.
For further experiments, clone 7, a library plasmid which contained full-
length calmyrin cDNA was digested with EcoRI and XhoI and subcloned
into pBluescript KS(
 
2
 
) or pGST/His T1 vector (Pharmacia Biotech, Inc.).
 
Yeast Two-Hybrid Liquid Assay
 
The specificity of the calmyrin interaction was tested against three PS2-
loop region constructs, two different PS1-loop constructs of which one was
further mutated to the corresponding PS2 sequence, one PS2 COOH-ter-
minal construct, and a lamin control. A conserved 31–amino acid loop re-
gion (designated PS2-loop C) was obtained by using primers B5
 
9
 
 and C3
 
9
 
to PCR generate a 93-bp fragment. The more divergent region of the loop
(designated PS2-loop D) was generated using primers D5
 
9
 
 and B3
 
9
 
. A
construct encoding the final 40 amino acids of PS2 (designated PS2-
Cterm) was created using primers E5
 
9
 
 and E3
 
9
 
. The corresponding loop B
and loop C regions in PS1 were PCR amplified using primers F5
 
9
 
 with F3
 
9
 
or G3
 
9
 
, respectively, from a full-length PS1 clone obtained from Dr. S.S.
Sisodia (University of Chicago, IL). The PS1-loop C region, which differs 
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by only three amino acids from the corresponding PS2-loop (containing a
threonine instead of a proline at position 281 (see Fig 1 A, numbered ac-
cording to PS1), a leucine in place of an isoleucine at position 282, and a
threonine for an alanine at position 291), was mutated at each of the three
divergent residues, singly, and in every possible combination to the cor-
responding PS2 sequence using appropriate PCR primers and the
QuikChange site-directed mutagenesis method (Stratagene). A control
bait construct which contained the first 31 amino acids of lamin B was ob-
tained by PCR with primers L5
 
9
 
 and L3
 
9
 
 from lamin B cloned in pBlue-
script KS(
 
2
 
) (Mical and Monteiro, 1998).
All PCR-amplified regions were digested with EcoRI and XhoI, cloned
into pEG202, and confirmed by DNA sequencing. These various baits
were transformed into EGY48 and found by immunoblotting of yeast ex-
tracts to express appropriately sized lexA-PS fusion polypeptides. Three
isolates from yeast transformed with the calmyrin in pJG4-5 (clone 7) plus
each PS bait or the control lamin bait were assayed for 
 
b
 
-galactosidase en-
zyme activity in liquid cultures using ONPG (
 
O
 
-nitrophenyl 
 
b
 
-
 
D
 
-galacto-
pyranoside) as a substrate (Reynolds and Lundblad, 1989).
 
Northern Blot Analysis
 
32
 
P-labeled DNA probes were prepared via standard random primer la-
beling of 100 ng of full-length calmyrin cDNA or human 
 
b
 
-actin cDNA
control. A human multiple tissue Northern (MTN) blot and a human
brain multiple tissue Northern blot II (CLONTECH Laboratories, Inc.)
were hybridized with the calmyrin probe at 68
 
8
 
C overnight, washed in
0.1
 
3
 
 SSC at 50
 
8
 
C, and exposed to film. The blots were then stripped of the
calmyrin probe and reprobed with the 
 
b
 
-actin control (CLONTECH Lab-
oratories, Inc.).
 
Bacterial GST Fusion Protein Expression
 
The original pGST construct or the pGST construct containing the com-
plete calmyrin sequence fused COOH-terminally and in-frame with GST
was transformed into CAG456 bacteria. Unfused GST and GST/calmyrin
fusion protein induction with IPTG, incubation with glutathione agarose,
and elution with reduced glutathione were as described in Janicki and
Monteiro (1997).
 
Cloning of Eukaryotic Expression Constructs
 
The pGEM-CMV vector, a CMV-driven expression plasmid containing a
COOH-terminal myc-tag (described in Janicki and Monteiro, 1997), was
used for protein expression in HeLa cells. A calmyrin construct containing
an in frame COOH-terminal myc epitope was created by PCR amplifying
the calmyrin fragment from pBS-calmyrin with primers M5
 
9
 
 and M3
 
9
 
 re-
sulting in a 
 
z
 
600-bp PCR product that was digested with SacII and SalI
and ligated into pGEM-CMV.
An NH
 
2
 
-terminal myc-tagged calmyrin construct was also created by
PCR using primer N5
 
9
 
 with primer N3
 
9
 
 to introduce eleven residues of the
myc epitope (Monteiro et al., 1994) followed by four residues encoded by
5
 
9
 
 untranslated calmyrin sequence linked to the complete calmyrin coding
sequence. The resulting 
 
z
 
600-bp PCR product was digested with SacII
and SalI and ligated into pGEM-CMV.
An untagged full-length calmyrin expression construct was created by
digesting pBS-calmyrin with SacII and XhoI, gel isolating the 
 
z
 
650-bp
fragment, and ligating it to SacII/SalI linearized pGEM-CMV. The clon-
ing and expression of both full-length PS2 and the PS2 construct deleted
of loop and COOH-terminal sequence [pPS2(268aa) 
 
1 
 
Myc] were de-
scribed previously (Janicki and Monteiro, 1997). Expression of full-length
wild-type neurofilament light (NF-L) subunit was achieved using the
CMV-NF-L expression construct (Lee et al., 1993).
 
Polyclonal Antibody Production
 
Purified GST/calmyrin protein and GST/PS2(NH
 
2
 
-terminal) fusion pro-
tein (described in Janicki and Monteiro, 1997) were sent to Covance Re-
search Products for inoculation into rabbits. The specificity of these rabbit
antibodies was determined by immunoblotting (Janicki and Monteiro,
1997) and immunofluorescent staining of HeLa cell transfected with
calmyrin or PS2. For immunoblotting, the anti-calmyrin and anti-PS2 anti-
bodies were used at a 1/500–1/700 dilution and detected with horseradish
peroxidase-conjugated goat anti-rabbit secondary antibodies and Super-
Signal Substrate (Pierce Chemical Co.).
 
HeLa Cell Culture and DNA Transfection
 
HeLa cells were grown in DME supplemented with 10% FBS and tran-
siently transfected with appropriate plasmid DNAs as calcium phosphate
precipitates (Janicki and Monteiro, 1997). Alternatively, 20 
 
m
 
g of DNA
and 2 
 
3
 
 10
 
6
 
 HeLa cells were electroporated at 960 
 
m
 
F and 0.3 kV.
 
Cell Staining and Immunofluorescence Microscopy
 
HeLa cells were transfected directly on glass coverslips, fixed, and anti-
body stained as described in Janicki and Monteiro (1997). Antibodies
used were rabbit anti-calmyrin serum (diluted 1:250), goat anti-PS2(NH
 
2
 
-
terminal) antibody (diluted 1:150; Santa Cruz Biotechnology, Inc.), rabbit
anti-lamin serum (diluted 1:200; Mical and Monteiro, 1998), rabbit anti-
NFL serum (diluted 1:250; generated in this lab using recombinant-puri-
fied, bacterially expressed, mouse neurofilament light chain), M30 Cy-
toDEATH mouse anti-cytokeratin 18 antibody (diluted 1:50; Boehringer
Mannheim), fluorescein- and rhodamine-conjugated donkey anti–rabbit,
anti–goat, and anti–mouse antibodies (Jackson ImmunoResearch Labora-
tories, Inc.). Fluorescence staining of cells was visualized on an inverted
Leica DM IRB microscope and images were captured using a Photomet-
rics SenSys camera and manipulated with IPLab Spectrum and Multi-
probe software (Scanalytics) on a Power Macintosh. Confocal microscopy
and image processing was performed using the 
 
3
 
100 objective of a Leica
confocal and imaging system (Leica Inc.) with the kind help of Dr. Timo-
thy Mical and Dr. Joseph Gall (Carnegie Institution, Baltimore, MD).
 
Mouse Tissue Lysates and Primary Cultures
 
Spleen, brain, kidney, liver, heart, and skeletal muscle tissues were dis-
sected from an adult mouse, chopped with a razor blade in 1–2 ml lysis
buffer (Monteiro and Mical, 1996), homogenized on ice, briefly sonicated
on ice, and centrifuged at 2,000 rpm for 5 min. Tissue lysate supernatants
were collected, their protein concentration was determined by the BCA
Protein Assay (Pierce), and 100 
 
m
 
g of each sample was separated by SDS-
PAGE, transferred to nitrocellulose filters, and immunoblotted with the
rabbit anti-calmyrin antibody.
Kidney and heart tissues from 8–12 2-d-old mice were chopped with a
razor blade, resuspended in 2 ml 0.25% collagenase in PBS, vortexed, in-
cubated at 37
 
8
 
C for 15 min, centrifuged, and washed 3
 
3
 
 with PBS. Cells
were cultured in EGM medium supplemented with BBE (Clonetics) and
10% FBS for 2–7 d. For immunofluorescence, cells were cultured directly
onto coverslips and fixed and stained as described above.
 
Cell Fractionation
 
Nondetergent soluble and insoluble fractions of HeLa cells were prepared
essentially as described by Gerace and Globel (1980). HeLa cells (
 
z
 
1 
 
3
 
10
 
6
 
) were collected 24 h after transfection by scraping the cells in ice-cold
PBS and centrifugation at 10,000 
 
g
 
. The cells were resuspended in 0.25 ml
10 mM triethanolamine-HCL (pH 7.4), 10 mM KCl, 1.5 mM MgCl
 
2
 
, 5 mM
iodoacetamide, and 1 mM Pefabloc (Boehringer Mannheim). After 10
min incubation on ice the cells were disrupted with 10 gentle strokes in a
0.5-ml Potter-Elvehjem homogenizer. Next, 0.25 ml 10 mM triethanola-
mine-HCL (pH 7.4), 270 mM KCl, 1.5 mM MgCl2, 5 mM iodoacetamide,
and 1 mM Pefabloc were added and after mixing, the homogenates were
centrifuged at 100,000 g for 15 min in a Beckman TLX ultracentrifuge.
The supernatants were removed and the pellets resuspended in lysis
buffer (Monteiro and Mical, 1996) to a volume equal that of their respec-
tive supernatants.
Triton X-100–treated HeLa cell fractions were prepared by lysing the
transfected cells in 0.5 ml ice-cold 1% Triton X-100, 10 mM triethanola-
mine-HCL (pH 6.9), 140 mM KCl, 1.5 mM MgCl2, 5 mM iodoacetamide,
and 1 mM Pefabloc. After 10 min incubation the lysates were centrifuged
at 140,000 g for 15 min. Supernatants were collected and the pellets resus-
pended in lysis buffer. Equivalent volumes of the supernatant and pellet
fractions of the detergent-treated and untreated cells were separated by
SDS-PAGE and immunoblotted using the rabbit anti-calmyrin antibody
or the rabbit anti-lamin antibody. The same cell fractionation procedure
was used on primary cell cultures prepared from mouse kidney.
Myristoylation Experiments
After transfection, sodium pyruvate to a final concentration of 1 mM and
0.1–0.2 mCi 3H-myristic acid (Amersham Life Science Inc.) were added to
the fresh media in each cell culture dish. At z24 h after transfection, cellsThe Journal of Cell Biology, Volume 145, 1999 1280
were scraped off the bottom of the dish and the media was collected and
centrifuged 5 min at 3,000 rpm. The cell pellet was washed with PBS, cen-
trifuged, resuspended in 400 ml lysis buffer (50 mM Hepes, 100 mM KCl,
0.3% NP40, 1 mM EDTA, 1 mM EGTA, pH 7.5, 1 protease inhibitor
cocktail with aprotonin, leupeptin, and PMSF; Boehringer Mannheim),
and homogenized on ice. Insoluble material was pelleted and the superna-
tant was collected and diluted with an equal volume of dilution buffer (50 mM
Hepes, 1 mM EDTA, and 1 mM EGTA, pH 7.5). 150 ml of the lysates
were incubated with 5 ml of antibody (rabbit anti-calmyrin, rabbit anti-
PS2, or rabbit control preimmune serum) for 2 h at 48C. 45 ml of a slurry of
protein A–Sepharose beads (Pharmacia Biotech, Inc.) was then added to
the lysates and incubated with rotamixing for another 1 h. The beads were
pelleted by centrifugation, and after removal of the supernatant, the beads
were washed four times with lysis/dilution buffer. All of the immunopre-
cipitate and one-sixth of the supernatant sample were separated by SDS-
PAGE. After Coomassie blue staining and destaining, the gel was soaked
for three 15 min changes in DMSO, immersed in 22% PPO (2,5-diphe-
nyloxazole) for 90 min, washed in water, dried, and exposed to film by flu-
orography for 1 wk to 2 mo.
Affinity Chromatography
After z24 h, mock or PS2-transfected HeLa cells (z1 3 106 cells) were
washed in ice-cold PBS, scraped into PBS, and pelleted by centrifugation
for 5 min at 3,000 rpm. The cells were resuspended in 400 ml of lysis buffer
(see myristoylation section), sonicated, and homogenized on ice. Insoluble
material was pelleted and the supernatant was collected and diluted with
an equal volume of dilution buffer. All of the soluble lysate was incubated
overnight at 48C with CNBr-activated Sepharose beads (Pharmacia Bio-
tech, Inc.) coupled with an equivalent amount (240 mg) of either purified
GST or GST/calmyrin. The Sepharose beads were then pelleted by cen-
trifugation and supernatant containing unbound protein was removed.
The beads were washed with 2.5 M KCl, resuspended in Laemmli buffer,
and 1/2 of the sample was separated by SDS-PAGE and immunoblotted
for the presence of PS2 using a goat anti-PS2(NH2-terminal) antibody.
Quantification of Cell Death
Duplicate dishes of HeLa cells (plated at z3 3 105/100 mM dishes) were
transfected with various combinations of pGEM-CMV-calmyrin, pGEM-
CMV-PS2, and control vector (a CAT basic expression vector; Promega).
After z48 h, floating cells from each dish were harvested by collecting
all of the media, centrifuging 5 min at 3,000 rpm, and removing all but
z0.5 ml of the supernatant. After vortexing, the exact volume of each cell
suspension was measured. Cell numbers were counted twice for each sam-
ple on a hemacytometer. These cell counts were adjusted according to the
initial resuspension volume to give the total number of floating cells per
dish. The counts for the two independent dishes of each transfection con-
struct combination were averaged and graphed. There was a direct corre-
spondence between floating cells and apoptotic cells, with z85% of float-
ing cells showing positive CytoDEATH staining.
Results
PS2-Loop Interaction Trap Identifies a
Calcium-binding Protein, Calmyrin
Using the yeast two-hybrid system, a human fetal brain
cDNA library was screened for proteins that bind the loop
region of PS2. Full-length PS2 was unsuitable as bait pre-
sumably because it could not be transported into the nu-
cleus due to the presence of hydrophobic transmembrane
domains. In addition, as it is one of the most divergent re-
gions between the presenilin proteins, we believed our
chances of finding PS2-specific interactors would be in-
creased. After finding that our initial PS2-loop construct
(residues 270–361) self-activated transcription, we trun-
cated the bait reducing it to the first 50 amino acids in or-
der to eliminate several acidic residues and designated it
PS2-loop B (B for bait; Fig. 1 A). The PS2-loop B bait con-
struct, the lacZ reporter plasmid, and human fetal brain
cDNA library plasmids were transformed into yeast, and
out of 1.5 3 107 primary transformants screened, 15 puta-
tive interactors were isolated. Isolated library prey plas-
mids were tested for their ability to reproduce the specific
interaction phenotype when coexpressed with the loop
bait but not with unrelated baits (such as human lamin B).
Clones that produced the specific interaction phenotype
were sequenced and identified via BLAST homology da-
tabase search. Interestingly, three of the interactors were
independent cDNAs all containing the full coding se-
quence of a recently identified calcium-binding protein,
but with varying NH2-terminal untranslated extensions.
Two other groups have recovered this calcium-binding
protein in yeast two-hybrid screens and have named it
CIB, for its calcium- and integrin aIIb–binding ability
(Naik et al., 1997), and KIP, due to its interaction with eu-
karyotic DNA-dependent protein kinase, DNA-PKcs (Wu
and Lieber, 1997). Rather than pick between these two
names we have chosen to refer to this protein as calmyrin
(for calcium-binding myristoylated protein with homology
to calcineurin) because it describes its inherent properties
without bias towards its multiple binding partners.
To quantify the binding specificity of calmyrin to the
PS2-loop and to determine if this protein also interacts
with the PS1 loop which is 45% identical in amino acid se-
quence, we measured the b-galactosidase activity in yeast
liquid assays. When cotransformed with calmyrin, the PS2-
loop B bait produced an 8.5-fold increase in b-galactosi-
dase activity over the lamin B negative control, while the
corresponding region of PS1 (PS1-loop B) produced only
a 1.9-fold increase in activity (Fig. 1 B). A PS2–COOH-
terminal construct, containing the COOH-terminal 39–
amino acid sequence downstream of the eighth TMD also
did not appear to interact with calmyrin.
To further map the binding site of calmyrin within the
PS2-loop, two new baits were constructed which divided
the loop into a conserved portion, loop C (28 out of the 31
amino acids are identical to PS1), and a divergent region,
loop D (only 33% identity to PS1; Fig 1 A). Since calmyrin
did not interact preferentially with the comparable loop
region of PS1 (PS1-loop B) we expected the calmyrin
binding site to be within the divergent region of the PS2-
loop sequence (PS2-loop D). To our surprise, the PS2-
loop D bait interacted very weakly with calmyrin, a 2.2-
fold increase over control (Fig. 1 B). However, the highly
conserved region of the PS2 loop, PS2-loop C, produced a
74-fold increase in activity (Fig. 1 C). In comparison, the
corresponding PS1-loop C construct increased activity
only 5.8-fold.
Although the two PS-loop C baits are highly conserved
in sequence, they differ by three amino acids, with PS1
containing threonine residues at positions 281 and 291 in-
stead of proline and alanine, respectively (see Fig. 1 A,
numbered according to PS1), and a leucine instead of an
isoleucine at position 282. We investigated how these
three divergent residues influenced calmyrin interaction
with the PS-loop C region in yeast two-hybrid assays by in-
troducing the PS2 amino acids into the PS1 bait, so that
each of the three divergent residues were mutated singly,
and in every possible combination, to the corresponding
PS2 sequence. These data indicated that all three residues
contributed in different and complex ways towards the in-Stabler et al. Interaction of Calmyrin with Presenilin 2 1281
teraction (Fig. 1 C). Interestingly, calmyrin interaction was
restored to approximately half the PS2 level by single mu-
tation of residue 281 to a proline, a residue which would be
predicted to introduce a kink in the loop. In comparison,
single mutation of residue 282 to an isoleucine did not in-
crease binding to any significant extent, whereas mutation
of residue 291 to an alanine increased binding to a third
that of the PS2 level. Double mutants confirmed the im-
portance of residues 281 and 291. When both proline and
alanine were present together (T281P, T291A) they in-
creased binding substantially, producing an approximately
twofold higher level of binding compared with the wild-
type PS2-loop bait. This mutant suggests that isoleucine at
residue 282 in PS2 may actually compromise binding, as
this would be equivalent to the triple substitution (T281P,
L282I, T291A; i.e., turning it back to the PS2 sequence).
Consistent with this expectation, isoleucine 282, when
present together with alanine 291, did not increase binding
above that of the latter alone, whereas paradoxically when
it was substituted together with proline 281 it increased
binding 1.7-fold higher than when proline was substituted
alone.
The 191–amino acid sequence of calmyrin has a number
of notable features (Fig. 2 A). Sequence comparison indi-
cates that calmyrin is most closely related to human cal-
cineurin B, the regulatory subunit of protein phosphatase
2B, sharing 25% identity and 44% overall similarity. The
protein contains two complete EF hands, a conserved mo-
tif involved in calcium binding, and in fact, was shown to
bind radiolabeled calcium in blot overlay assays (Naik et al.,
1997). The protein also contains an NH2 consensus myris-
toylation site, a cotranslational modification involved in
targeting proteins to membranes. To verify the size and
expression pattern of calmyrin transcripts, Northern blot
analysis of poly(A)1 RNA isolated from multiple adult
human tissues was performed (Fig. 2 B). The calmyrin
probe hybridized to an z1.2-kb transcript that was ubiqui-
tously expressed in the tissues examined, extending the ev-
Figure 1. Presenilin loop
constructs and their interac-
tion with calmyrin. (A) The
general topology of the mul-
tiple transmembrane prese-
nilin protein is diagrammed
and the loop region amino
acid sequence comparison
between PS1 and PS2 is pro-
vided. The first 50 amino ac-
ids of the PS2-loop desig-
nated loop B (large dashed
line), were used as the bait in
the interaction trap. In the
liquid assay binding study
loop B was further subdi-
vided into a conserved region
(loop C, solid line) and a
more divergent region (loop
D, small dashed line). Boxes
enclose identical (dark
shade) and similar (light
shade) residues. (B and C)
Results of yeast two-hybrid
liquid assay using the baits
described in (A) are graphed
with standard errors shown.The Journal of Cell Biology, Volume 145, 1999 1282
idence that it is widely expressed (Naik et al., 1997; Wu
and Lieber, 1997) and implying that it plays a common
function in most if not all cells. Although mRNA expres-
sion was relatively low in brain, a Northern blot of specific
brain regions showed that the expression of calmyrin tran-
scripts was easily detectable and fairly uniform (Fig. 2 C).
Tissue Distribution and Subcellular Localization of 
Endogenous Calmyrin Protein
To study further the calmyrin protein, rabbit polyclonal
anti-calmyrin antibodies were generated to affinity-puri-
fied GST/calmyrin fusion protein (Fig. 3 A, lane 7). By
immunoblotting, these antibodies appear to be highly
specific for calmyrin as they reacted only with the appro-
priately sized polypeptides (z22-25 kD) in HeLa cells
overexpressing calmyrin cDNAs (Fig. 3 B). Lane 1 of Fig.
3 B shows that at the depicted exposure time the antibod-
ies failed to detect any endogenous calmyrin in untrans-
fected lysate. Only after prolonged exposure did a faint
calmyrin band appear (data not shown), indicating that en-
dogenous levels of this calcium-binding protein are rela-
tively low in HeLa cells. However, consistent with our
Northern blot analysis, an endogenous immunoreactive
band at z22 kD was detected in human adult brain lysate
(Fig. 3 C). The anti-calmyrin antibodies also successfully
detected the mouse form of this protein in several mouse
tissue lysates (Fig. 3 D) due to the high conservation be-
tween the human and mouse calmyrin proteins (only five
dissimilar residues; Saito et al., 1999). The significance of
the faster migrating immunoreactive band in mouse skele-
tal muscle (Fig. 3 D, lane 6) has not been determined.
Since the subcellular localization of calmyrin was un-
known, we used the anti-calmyrin antibody to determine
its distribution in mammalian cells by indirect immunoflu-
orescence microscopy. In primary cultures from mouse
heart tissue endogenous calmyrin localized to the nucleus
and in a reticular-like pattern throughout the cytoplasm
(Fig. 3 E). This staining was clearly distinguishable from
the nonspecific background produced when probing with
rabbit preinnoculation serum (data not shown), and more-
over, this staining pattern was reproduced by overexpres-
sion of calmyrin upon transfection (see below).
Calmyrin Is Myristoylated and Membrane Associated
As PS2 is a transmembrane protein and our yeast two-
hybrid findings indicated that calmyrin interacts with PS2,
the membrane targeting potential of the consensus myris-
toylation site in calmyrin especially intrigued us. To deter-
mine whether calmyrin is myristoylated in vivo, we added
3H-myristic acid to the media of HeLa cells transfected
with untagged calmyrin. For comparison, HeLa cells were
also transfected with calmyrin constructs that had myc tags
fused at either the NH2- or COOH-terminal ends of the
protein. The prediction was that the myc tag (MEQKLI-
SEEDLN) fused at the NH2-terminal end would disrupt
myristoylation since it moved the glycine residue that is es-
sential for myristoylation more downstream (Olshevskaya
et al., 1997). After 24 h, the cells were lysed and calmyrin
was immunoprecipitated with the anti-calmyrin antibody.
Myristoylated proteins were visualized by fluorography af-
ter SDS-PAGE (Fig. 4 A). The fluorograph of labeled
HeLa cell lysates indicated immunoprecipitated C-myc–
tagged calmyrin and untagged wild-type calmyrin were
myristoylated as evident by incorporation of the radioac-
tive 3H-myristic acid label (band in lanes 4 and 6 indicated
by an arrows) while, as expected, the N-myc tagging of the
protein prevented myristoylation (absence of band in lane
2). The lower panel of this figure contains an immunoblot
of these same HeLa cell lysates to show that both NH2-
and COOH-terminally tagged calmyrin proteins were
expressed efficiently and to equivalent levels, whereas
untagged calmyrin accumulated at lower protein levels,
explaining the fainter myristoylated calmyrin band seen in
lane 6 as compared with lane 4. In fact, when the ratio of
Figure 2. Calmyrin amino
acid sequence and transcript
expression pattern. (A) The
complete amino acid se-
quence of calmyrin is shown
in comparison to human cal-
cineurin B. The two con-
served calcium-binding EF
hands are circled and the two
EF hands that are disrupted
in calmyrin are noted by a
dashed line. (B) The human
multiple tissue Northern blot
and (C) the human brain
multiple tissue Northern blot
were first probed with 32P-
labeled calmyrin cDNA,
stripped, and subsequently
probed with 32P-labeled
b-actin cDNA as a control.
The  z1.2-kb hybridization
band corresponds to the ex-
pected size for calmyrin tran-
script.Stabler et al. Interaction of Calmyrin with Presenilin 2 1283
calmyrin protein to radioactive 3H-myristic acid labeling is
compared for C-myc–tagged and wild-type calmyrin pro-
teins they are similar, which is expected since myristoyla-
tion is thought to occur cotranslationally (Wilcox et al.,
1987). The reason for higher expression of C- and N-myc–
tagged calmyrin proteins is not known but perhaps fusion
of the myc epitope affects protein stability or toxicity, al-
lowing the proteins to accumulate to higher levels. Similar
attempts to demonstrate myristoylation of endogenous
calmyrin in mouse and human cells were unsuccessful, pre-
sumably because of low protein expression or the slow
turnover of the protein.
Once we established that calmyrin was indeed myristoy-
lated, next we determined whether this protein was associ-
ated with the membranes of fractionated cells. Transfected
HeLa cells were fractionated in the absence of any de-
tergents into a soluble (cytosolic) supernatant and an in-
soluble (membrane and cytoskeletal) pellet. Equivalent
amounts of supernatant and pellet cell fractions were sep-
arated by SDS-PAGE and immunoblotted for the pres-
ence of lamins and calmyrin (Fig. 4 B, lanes 1 and 2).
Lamins A and C, cytoskeletal components used as a con-
trol of the fractionation process, were detected as 68- and
66-kD polypeptides in the insoluble pellet as expected
(Gerace and Blobel, 1980; Mical and Monteiro, 1998). The
majority (.85%) of the calmyrin was found in the insolu-
ble fraction. Since this manner of cell fractionation does
not distinguish membrane components from other insolu-
ble structures, the cells were also fractionated in the pres-
ence of 1% Triton X-100 which solubilizes membranes.
After this procedure, the calmyrin protein shifted to the
soluble (membrane) fraction whereas the lamins, as ex-
pected, remained insoluble (Fig. 4 B, lanes 3 and 4). The
same fractionation was performed on primary cultures of
mouse kidney and showed an analogous pattern of mem-
brane localization for endogenous calmyrin (Fig. 4 B,
lower panel). Interpreted together, these cell fractionation
results provide strong biochemical evidence that calmyrin
is associated with cell membranes.
Calmyrin Accumulates in the Nucleus and Cytoplasm, 
but When Coexpressed with PS2 these Two Proteins 
Colocalize at the ER
On account of the faint staining of endogenous calmyrin in
primary and established cell cultures, calmyrin was forc-
ibly expressed in HeLa cells by transient transfection of
untagged and myc-tagged calmyrin constructs for further
immunofluorescent localization studies. As seen in Fig. 5
A, cells expressing untagged calmyrin had strong staining
in the nucleus and cytoplasm, a pattern very similar to the
subcellular localization of endogenous calmyrin detected
in mouse cells. At higher magnification, many of these
transfected cells showed clear calmyrin staining of thin
Figure 3. Expression and pu-
rification of GST/calmyrin
protein, characterization of
anti-calmyrin antibodies, and
detection of endogenous
calmyrin protein. (A) Coo-
massie blue–stained gel doc-
umenting the induction and
purification of GST (lanes
1–3) and GST/calmyrin (lanes
5–7). Uninduced bacterial ly-
sate (lanes 1 and 5), induced
lysate (lanes 2 and 6), glu-
tathione agarose affinity-
purified proteins (lanes 3 and
7), and molecular mass
markers (4) are displayed.
The purified z45-kD GST/
calmyrin fusion protein
shown in lane 7 was inocu-
lated into rabbits for the pro-
duction of polyclonal anti-
bodies. (B) Immunoblot of
HeLa cell lysates probed
with rabbit anti-calmyrin se-
rum. HeLa cells were trans-
fected with C-myc calmyrin
(lane 2), N-myc calmyrin
(lane 3), and wild-type calmyrin (lane 4), or were mock transfected (lane 1). The anti-calmyrin antibodies react with the appropriate size
polypeptides only in calmyrin transfected cells. Note the absence of nonspecific background staining and the inability to detect any en-
dogenous calmyrin in HeLa cells at this exposure. (C) Immunoblot of human brain lysate loaded at 100 mg total protein and probed
with rabbit anti-calmyrin serum. Please note endogenous calmyrin in brain migrates as a 22-kD protein. (D) Immunoblot of various
mouse tissues loaded at 100 mg total protein and probed with anti-calmyrin to detect endogenous levels of calmyrin. (E) Immunofluo-
rescent localization of endogenous calmyrin in mouse heart primary cell culture indicates that this protein resides in the nucleus and
throughout the cytoplasm. Bar, 5 mm.The Journal of Cell Biology, Volume 145, 1999 1284
projections from the cell surface as well as a reticular
staining in the cytoplasm consistent with membrane tar-
geting to the plasma membrane and ER (Fig. 5 C). Cells
expressing C-myc calmyrin had greater variation in stain-
ing with many showing prominent localization to the ER
and plasma membrane and often less staining in the nu-
cleus (Fig. 5 D). Double immunofluorescence staining for
calreticulin, an ER marker protein, and calmyrin showed
that within the cytoplasm a notable portion of calmyrin
colocalized with calreticulin (data not shown), corroborat-
ing the impression that in these transfected cells calmyrin
localization includes, but is not limited to, ER membranes.
In contrast, cells expressing N-myc calmyrin showed pre-
dominant nuclear staining, more diffuse cytoplasmic stain-
ing, and less staining at the plasma membrane which was
especially evident in low expressing cells (Fig. 5 E). This
observed reduction in membrane association was not sur-
prising considering our previous finding that this NH2-ter-
minally tagged construct failed to be myristoylated. To
address whether the bright nuclear staining was due
to calmyrin localization within the nuclear envelope or
throughout the nucleoplasm, we double stained wild-type
calmyrin transfected HeLa cells for calmyrin and lamins
A/C. According to confocal microscopy, lamins A and C
had rim fluorescence (Fig. 5 G) consistent with their
known localization as a caged meshwork of filaments teth-
ered to the inner nuclear envelope (see Mical and Mon-
teiro, 1998). In the same confocal Z-section (1.0-mm
section) where lamins had rim fluorescence, calmyrin
immunoreactivity was present throughout the cell and
clearly within the nucleoplasm (Fig. 5 F). Overall, these
results indicated calmyrin localizes to many different cel-
lular compartments, consistent with the protein having dy-
namic targeting properties. Of particular interest to this
study was the comparison of calmyrin and PS2 staining
patterns when overexpressed individually in HeLa cells.
Although the two staining patterns overlapped in part, es-
pecially the ER reticular staining of untagged and C-myc
calmyrin, PS2 staining was readily distinguishable by its
exclusive ER and nuclear envelope staining pattern (Fig.
5 H).
When calmyrin was coexpressed with PS2, its staining
pattern was dramatically altered such that it colocalized al-
most completely with PS2 (Fig. 6). As exemplified by the
two cells shown in panels A and B, the calmyrin protein
was less apparent in the nucleus in coexpressing cells than
in cells transfected solely with calmyrin (Fig. 5 A). An-
other indication that these two proteins bind each other
was seen in a small subset of cells where calmyrin and PS2
colocalized distinctively in unusual intranuclear spots (Fig.
6 C). The intranuclear spots did not colocalize with anti-
centromere staining by double immunofluorescent micros-
copy (data not shown) suggesting that they are distinct
from the PS-immunoreactive structures observed by Li et al.
(1997). The shift in calmyrin localization and the nearly
identical staining patterns between PS2 and calmyrin (see
merged images) in these coexpressing cells provide per-
suasive evidence that these two proteins interact in vivo.
Furthermore, when calmyrin was cotransfected with a PS2
construct deleted of the loop and all sequence COOH-ter-
minal of it, the staining patterns displayed significantly less
overlap; as seen by patchy aggregates of PS2 which ex-
cluded calmyrin (Fig. 6 D, indicated by arrows). The fail-
ure of this PS2 deletion construct to completely colocalize
with calmyrin in aggregates, which contrasts with the colo-
calization of the wild-type PS2 protein and calmyrin in nu-
clear inclusions, enhances our view that the PS2-loop re-
gion facilitates binding of calmyrin.
Affinity Chromatography and Immunoprecipitation 
Confirm Binding between Calmyrin and PS2
Despite results from yeast two-hybrid assays, cell fraction-
ation experiments, and histological colocalization, which
all consistently argue for an interaction between calmyrin
and PS2, our initial attempts at demonstrate binding of the
two proteins in vitro proved difficult. After trying various
combinations of affinity chromatography and immunopre-
cipitation with GST fusion proteins, in vitro translated
proteins, and HeLa cell–expressed proteins under several
different buffer conditions, two of these experiments pro-
vided further evidence for the binding of calmyrin and
PS2. First, HeLa cell lysates of overexpressed PS2 were
incubated with purified GST-calmyrin, or GST alone,
(shown in Fig. 3 A) that had been covalently coupled to
Sepharose. The two Sepharose columns were then washed,
Figure 4. Immunoprecipitation of myristoylated calmyrin and lo-
calization of calmyrin to the membrane fraction. (A) Fluorogra-
phy of myristoylated proteins immunoprecipitated with rabbit
anti-calmyrin from HeLa cells after transfection with N-myc
calmyrin (lane 1 and 2), C-myc calmyrin (lane 3 and 4), or wild-
type calmyrin (lane 5 and 6) and 24 h incubation with 3H-myristic
acid. The cell lysates (L) and immunoprecipitated (IP) samples
are shown. The myristoylated calmyrin band is present in lanes 4
and 6 (indicated by the arrows), but absent from lane 2. The
lower panel shows an immunoblot of the supernatants (S) and
immunoprecipitants (IP) of these same transfected cell lysates to
confirm the expression level and successful immunoprecipitation
of calmyrin. (B) Immunoblotting of calmyrin-expressing HeLa
cell lysates for lamins A and C (68 and 66 kD) and calmyrin (22
kD) after fractionation in the absence (2) of detergent (lanes 1
and 2) or in the presence (1) of 1% Triton X-100 (lane 3 and 4)
into a soluble supernatant (S) and an insoluble pellet (P). The
lower panel shows the identical fractionation of endogenous
calmyrin in mouse kidney primary cell culture.Stabler et al. Interaction of Calmyrin with Presenilin 2 1285
Figure 5. Immunofluorescent localization of calmyrin protein in transfected HeLa cells. (A and B) Field of two cells transfected with
wild-type calmyrin and stained with anti-calmyrin (A) and DAPI (B) reveals that the calmyrin antibody is specific since the lower-right
untransfected cell (see arrow) has a bright DAPI stained nucleus but has no fluorescein calmyrin staining. In the cell overexpressing
calmyrin, the protein localizes to the nucleus and cytoplasm. Note that within the nucleus, calmyrin accumulation closely resembles the
DAPI chromatin staining. (C) Close-up from a calmyrin-expressing cell to highlight the localization of calmyrin to the plasma mem-
brane projections. (D) The fluorescein staining pattern of cells overexpressing C-myc calmyrin appears slightly different from (A) with
less of the protein in the nucleus. (E) Contrastingly, N-myc calmyrin protein accumulates predominantly in the nucleus and produces a
more diffuse cytoplasmic staining. (F and G) Confocal images of a cell overexpressing wild-type calmyrin and stained with anti-calmyrin
(F) and anti-lamin (G) indicate that calmyrin localization is not restricted to the nuclear envelop. (H) An example of the ER staining
pattern of overexpressed PS2 is also shown. Bar, 5 mm.The Journal of Cell Biology, Volume 145, 1999 1286
and retention of PS2 was determined by immunoblotting
with anti-PS2 antibody. Fig. 7 A shows that GST-calmy-
rin Sepharose bound PS2 with approximately  threefold
greater affinity (lane 4, see arrow) than control GST-cou-
pled Sepharose (lane 3). The second verification of bind-
ing was the coimmunoprecipitation of myristoylated cal-
myrin protein from cotransfected HeLa cell lysates with
anti-PS2 antibodies (Fig. 7 B, lane 5). The myristoylated
calmyrin protein did not immunoprecipitate when the pre-
immune anti-PS2 serum was used (Fig. 7 B, lane 6) but,
as expected, could be immunoprecipitated with the anti-
calmyrin antibody (Fig. 7 B, lane 4).
Overexpression of Calmyrin Causes Apoptosis
Since we had previously shown that overexpression of PS2
in HeLa cells causes apoptosis (Janicki and Monteiro,
1997), we wished to determine what effect overexpression
Figure 6. Immunofluorescent colocalization of calmyrin with PS2 in transfected HeLa cells. (A–C) HeLa cells cotransfected with wild-
type calmyrin and full-length PS2 were stained 24 h after transfection with rabbit anti-calmyrin and goat anti-PS2 antibodies. Green
(left-hand panels) is the fluorescein labeled calmyrin, red (center panels) is the rhodamine labeled PS2, and yellow (right-hand panels)
is a merged image indicating when the fluorescein and rhodamine signals colocalize. As exemplified by the three selected cells, when co-
expressed calmyrin shows a pattern of localization nearly identical to PS2. While most cotransfected cells show a staining pattern consis-
tent with ER localization (A and B), a small subset of cells appear to colocalize calmyrin and PS2 in punctuate intranuclear aggregates
(C). (D) Similar staining of HeLa cells cotransfected with wild-type calmyrin and loop/COOH-deleted PS2 show patchy aggregates (see
arrows) of PS2 (red) which exclude calmyrin (green). Bar, 5 mm.Stabler et al. Interaction of Calmyrin with Presenilin 2 1287
of calmyrin would have on cell viability. To detect apopto-
sis we used the M30 CytoDEATH antibody. This mouse
monoclonal binds an epitope of cytokeratin 18 which is ex-
posed only after caspase cleavage, an early event in apop-
tosis (Caulin et al., 1997; Boehringer Mannheim). Consis-
tent with our previous findings, Fig. 8 A shows that a
subset (two out of three) of cells overexpressing PS2 ap-
peared apoptotic (notably only those that had rounded
up) according to both CytoDEATH positive staining and
condensed nuclei. Similarly, when calmyrin was overex-
pressed, analogous apoptosis was observed (Fig. 8 B).
Cotransfection of PS2 and calmyrin induced even higher
apoptosis. To convey more clearly the high levels of apop-
tosis that resulted from overexpressing these two proteins,
example images captured at low magnification are pro-
vided. Fig. 8 C shows that at 16 h after cotransfection
almost 13% of PS2-expressing cells (which presumably
also expressed calmyrin since PS2 and calmyrin staining
showed a near 1:1 correspondence [data not shown]) on
coverslips were positive for CytoDEATH staining. By 40 h
the proportion of apoptotic cells had increased to z50%
of the PS2-stained cells. The high level of apoptosis seen
on coverslips was striking, especially since this method
only captured a brief “window” of the cells progression
into apoptosis as during programmed cell death HeLa
cells lose their adherence on coverslips and float away into
the media. This phenomenon explains the reduction in to-
tal cells, and most notably PS-expressing cells (only 10
cells), remaining on the coverslip at 40 h after cotransfec-
tion (Fig. 8 D). In the examples shown in Fig. 8 only a sub-
set of PS overexpressing cells were apoptotic, indicating a
time-dependent process, whereas the corollary that all
apoptotic cells were also overexpressors always held true.
In contrast when a control protein, the neurofilament light
(NF-L) subunit, was overexpressed in HeLa cells (Fig. 8
E), minimal apoptosis (, 1%) was detected and total cell
counts and expression levels remained high even at 40 h. It
is remarkable that the single apoptotic cell in this field did
not stain for NF-L and that, conversely, there are several
rounded-up and highly expressing cells (presumably those
in mitosis), none of which appeared apoptotic. Fields of
cells overexpressing calmyrin or PS2 individually showed
levels of apoptosis above the neurofilament background,
but less than coexpressors. Unfortunately, due to variation
between (and even within) coverslips, this method did not
prove suitable for statistically significant quantification.
Because CytoDEATH labeling on coverslips only cap-
tured a narrow “window” of cells undergoing apoptosis,
we decided to quantify the total amount of cell death accu-
mulated over time by counting the total number of float-
ing cells in the media after transfection with various
amounts of plasmid DNAs encoding calmyrin and PS2.
This simple method was more reliable in quantifying cell
death. As graphed in Fig. 9, transient overexpression of
PS2 increased cell death in a dose-dependent manner,
whereas cell death induced by calmyrin overexpression
reached a plateau at 10 mg of transfected DNA. More in-
terestingly, when both proteins were coexpressed in the
linear cell death range of their respective DNAs, cell death
increased 5.9-fold over the control, compared with 2.7-
and 2.4-fold for the same respective transfection amounts
of calmyrin and PS2 individually, suggesting that these two
proteins have additive effects in promoting cell death.
When these floating cells were collected and stained with
the CytoDEATH antibody, z85% of the cells stained
positive for this marker of apoptosis, bolstering our belief
that counting floating cells is a reliable measure of cell
death.
Discussion
In this study, we demonstrate by several criteria that hu-
man PS2 protein interacts with a recently discovered cal-
cium-binding protein which we refer to as calmyrin. First,
calmyrin interacts with PS2-loop sequence in yeast two-
hybrid assays. Second, the two proteins bind to each other
by affinity chromatography and can be coimmunoprecipi-
tated. Third, the two full-length proteins colocalized when
coexpressed in vivo. The interaction of calmyrin with PS2
is also noteworthy since it is the first protein, to our knowl-
edge, that interacts preferentially with PS2 (at least by
yeast two-hybrid analysis) suggesting distinct functions for
the highly homologous presenilin proteins.
Two lines of evidence favor the PS2-loop region as the
critical site of calmyrin interaction: reduced in vivo colo-
calization when calmyrin was coexpressed with a loop-
deficient PS2 construct and increased yeast liquid culture
binding of calmyrin to the PS2-loop rather than the PS2–
COOH-terminal domain. Deletion analysis indicated that
calmyrin binding was mediated primarily by the NH2-ter-
minal 31 amino acids of the PS2-loop. Remarkably, de-
Figure 7. Affinity chromatography and coimmunoprecipitation
provide further evidence for binding between calmyrin and PS2.
(A) Immunoblot of PS2-expressing HeLa cell lysates (L) which
were affinity purified (AP) over GST-sepharose or GST/
calmyrin sepharose probed with goat anti-PS2. The PS2 trans-
fected lysate (1), untransfected lysate affinity purified over GST-
sepharose (2), PS2 transfected lysate affinity purified over GST-
sepharose (3), and PS2 transfected lysate affinity purified over
GST/calmyrin-sepharose (4) are shown. The arrow indicates the
PS2 band which appears three-fold more intense in lane 4 than in
lane 3. (B) Fluorography of myristoylated proteins immunopre-
cipitated with rabbit anti-calmyrin (lanes 1 and 4), rabbit anti-
PS2 (lanes 2 and 5), or rabbit preimmune serum (lanes 3 and 6)
from C-myc calmyrin and PS2 cotransfected HeLa cells incu-
bated for 24 h with 3H-myristic acid. Supernatants (S) and immu-
noprecipitates (IP) are shown. Arrows indicate a more promi-
nent myristoylated calmyrin band in lanes 4 and 5 compared with
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spite only a three–amino acid difference, the comparable
loop region of PS1 interacted with less than one-tenth the
strength in similar yeast two-hybrid assays. Site-directed
mutagenesis in which the three divergent PS2 residues
were introduced singly and in double combinations into
PS1 indicated that, in fact, all three amino acids produce
variable affects on the specificity of calmyrin for PS2. Par-
ticularly interesting was the pronounced increased in bind-
Figure 8. Immunofluorescent staining with CytoDEATH indicates that overexpression of PS2 and calmyrin increases HeLa cell apop-
tosis. (A) An example field of four cells shows that two of the three cells overexpressing PS2 are apoptotic according to CytoDEATH
positive staining and condensed nuclei. (B) Similarly, an example field of eight cells shows that both cells which overexpress calmyrin
also appear apoptotic. (C) 103 field of calmyrin and PS2 cotransfected cells after 16 h. Total cells in the field are indicated by DAPI
staining, expressing cells are labeled with anti-PS2 antibody (staining for the presence of PS2 and calmyrin in cotransfected cells showed
a near 1:1 correspondence between the overexpression of these two proteins), and apoptotic cells are detected with the CytoDEATH
anti-cytokeratin 18 antibody. Note the presence of .30 apoptotic cells which all also stain positive for PS2 expression. (D) 103 field of
calmyrin and PS2 cotransfected cells after 40 h. Note the reduction in total cells and the lower percentage of PS2-expressing cells at this
later time point. (E) 103 field of control neurofilament-transfected cells after 40 h. Please note that even at this later time point, a high
percentage of anti-neurofilament positive cells remain, while in contrast only one CytoDEATH apoptotic cell can be detected.Stabler et al. Interaction of Calmyrin with Presenilin 2 1289
ing conferred by the conversion of a threonine at positions
281 and 291 in PS1 to proline and alanine, respectively. In
contrast, the leucine at position 282 in PS1 when converted
to isoleucine as in PS2 caused pleotrophic effects, increas-
ing, decreasing, and inducing no change in interaction de-
pending on its context with the other two residues. These
data suggest that minor alterations in the sequence of the
PS loop induce conformational changes in this region with
dramatic consequences to protein–protein interactions.
Furthermore, the loop region is a site associated with
several PS-processing phenomena, including proteolytic
cleavage, caspase cleavage, as well as abnormal splicing
(Perez-Tur et al., 1995; Thinakaran et al. 1996; Kim et al.,
1997; Loetscher et al., 1997; reviewed by Hass, 1997).
Apart from calmyrin, several other proteins have been
found to interact with the PS-loop, namely, g-catenin, fil-
amin, calselinin, mu-calpain, and armadillo protein p007
(Zhou et al., 1997; Buxbaum 1998; Murayama et al., 1998;
Shinozaki et al., 1998; Zhang et al., 1998; Stahl et al.,
1999). Our data showing that minor (single amino acid)
alterations in the loop sequence can produce dramatic
changes in protein binding not only has implications in
terms of calmyrin function, but may also have important
consequences for the other processing events and binding
partners associated with this region. Therefore, it is not
surprising that many FAD mutations map to the PS1 loop.
In addition to the importance of protein–protein inter-
actions for localization, our immunofluorescence micros-
copy and biochemical fractionation studies indicate that
the myristoylation of calmyrin is important for the dy-
namic targeting of this protein to several subcellular com-
partments including: the cytoplasm, long projections of the
plasma membrane, and the nucleoplasm. Elegant studies
of recoverin, a myristoylated calcium-binding protein in-
volved in signaling in the retina, have established that this
protein alternates between conformations in which the
myristoyl group is exposed or sequestered, conformations
that are dependent on calcium binding (Kennedy et al., 1996;
Ames et al., 1997). These calcium-myristoyl switches are a
known mechanism for protein targeting and signal trans-
duction. Radiolabeling and biochemical studies show that
calmyrin is myristoylated and associated with membranes.
At present, we cannot clearly tease apart the roles that
myristoylation and protein–protein interactions play in the
in vivo targeting of calmyrin to membranes. In fact, our
evidence suggests that both are important. Yeast two-
hybrid assays with loop constructs containing site-directed
mutations clearly show the importance of protein–protein
interactions in mediating the association between calmyrin
and the integral membrane protein, PS2. Additionally, fu-
sion of the Gal4-acidic blob sequence at the NH2-terminal
end of calmyrin in the yeast two-hybrid clones would be
expected to prevent this fatty acid modification suggesting
that myristoylation is not essential for the interaction.
Paradoxically, however, it is the myristoylated form of
calmyrin that we were able to show coimmunoprecipitated
with PS2. Perhaps insertion of the myristoyl group into the
lipid bilayer initiates a conformational change that en-
hances the affinity of calmyrin for PS2. Analogously, the
Gal4-acidic blob may have maintained calmyrin in the
conformation that was more prone to binding PS2.
Cells overexpressing calmyrin proteins capable of being
myristoylated showed greater variation in staining pat-
terns often with increased targeting of calmyrin to the cy-
toplasm and plasma membrane suggesting that myristoy-
lation may be involved in this dynamic behavior. The
calmyrin that localized to the cytoplasm had a reticular-
like staining pattern which colocalized with PS2 staining
when the two proteins were coexpressed. We believe that
the reticular staining represents targeting of calmyrin pro-
tein to the ER since we and others have shown that over-
expressed PS2 was localized to the nuclear envelope and
ER (see Kovacs et al., 1996; Janicki and Monteiro, 1997).
Interestingly, in PS2-cotransfected cells relatively little
calmyrin was present in the nucleus, and instead, the en-
tire population almost completely colocalized with PS2 at
the ER. This redistribution to the ER is consistent with
the stoichiometric change of binding sites available for
calmyrin once PS2 was overexpressed. However, the pos-
sibility that PS2 expression may alter processing or intra-
cellular targeting of calmyrin can not be ruled out.
As myristoylation is known to be important for mem-
brane targeting, it is curious that a significant pool of
calmyrin is present within the nucleoplasm despite the
lack of a classical nuclear localization signal. Calmyrin is
small enough to passively diffuse through the nuclear
pores (proteins z65 kD and larger must be actively trans-
ported) and may be sequestered within the nucleoplasm
by binding to nuclear resident proteins such as DNA-PKcs
which has also been shown to bind calmyrin in yeast two-
hybrid assays (Wu and Lieber, 1997). The localization of
calmyrin to the long projections of the plasma membrane
Figure 9. Quantification of cell death due to overexpression of
PS2 and calmyrin. Floating cells from duplicate plates of HeLa
cells transfected with a total of 15 mg of DNA containing control
vector, increasing amounts of calmyrin, increasing amounts of
PS2, or both calmyrin and PS2, were collected after 48 h. The
number of floating cells per dish exceeding the mock transfection
background counts are graphed with standard errors shown.The Journal of Cell Biology, Volume 145, 1999 1290
may similarly represent binding to calmyrin’s other known
interactor, aIIb-subunit of integrin. These results indicate
that calmyrin may traffic between several proteins and fac-
tors suggesting a role for calmyrin in complex signaling
processes. How these processes relate to AD, and/or
apoptosis is not known but it is interesting that Volado, a
novel integrin which dynamically mediate cell adhesion
and signal transduction, was recently identified as a new
memory mutant in Drosophila (Grotewiel et al., 1998).
Also DNA-PKcs is the only known eukaryotic protein ki-
nase activated by DNA double-strand breaks which is a le-
sion induced during apoptosis (reviewed McConnell and
Dynan, 1996; Sheih et al., 1997). The possibility that
calmyrin, integrins, DNA-PKcs, and PS2 are in any way
connected or involved in human diseases is intriguing, yet
speculative.
In hypothesizing a physiologic role for the interaction
between PS2 and calmyrin, we are especially interested in
exploring the involvement of calcium and apoptosis. It is
noteworthy that calsenilin, another Ca21-binding protein
with sequence similarity to recoverin, binds to the COOH-
terminal region of presenilin proteins and like calmyrin re-
distributes with presenilin proteins in cotransfected cells
(Buxbaum, et al., 1998). Calmyrin does not share a high
degree of amino acid similarity to calsenilin, instead the
protein sequence of calmyrin is most homologous to hu-
man calcineurin B, the regulatory subunit of the Ca21-
calmodulin–dependent protein phosphatase 2B, which
plays important roles in stress, apoptosis, cell calcium sig-
naling, and signal transduction (see Guerini, 1997; Crab-
tree, 1999; Wang et al., 1999). The greatest homology is
found in the regions surrounding calcineurin B’s four cal-
cium-binding EF hand motifs and its NH2-terminal myris-
toylation site. Although these regions are relatively well
conserved, sharing 44% overall similarity, calmyrin ap-
pears to have only two functional EF hands as the two
NH2-terminal motifs contain several insertions that are
predicted to disrupt calcium binding. Naik et al. (1997)
have demonstrated that calmyrin can indeed bind calcium,
but it is unknown whether this property regulates phos-
phatase activity. If calmyrin behaves similarly to cal-
cineurin B in phosphatase regulation, it may have some
relevance to AD where there is speculation that PHF for-
mation and tau hyperphosphorylation occurs due to mis-
regulation of protein phosphatases or kinases (Matsuo et al.,
1994; Gong et al., 1996; Kayyali et al., 1997).
Our cell death findings imply that the binding of cal-
myrin to PS2 may be related to PS2 function in apoptosis.
In a previous study we found that overexpression of PS2 in
HeLa cells induced apoptosis. The current finding that co-
expression of calmyrin with presenilins in HeLa cells in-
creased apoptosis suggests that the two act in concert in a
pathway or pathways regulating cell death. Although we
have not determined the pathway through which the two
proteins function during programmed cell death, the fact
that calmyrin is a calcium-binding protein (Naik et al.,
1997) raises some obvious possibilities. First, calmyrin may
“sense” Ca21 changes and subsequently regulate PS2 func-
tion. Alternatively, PS2 proteins (including FAD mutants)
may alter calcium homeostasis resulting in a change in cal-
cium binding by calmyrin which could then trigger a signal
transduction cascade. This latter possibility is attractive
since overexpression of presenilins has been shown to
cause perturbations in calcium homeostasis (Guo et al.,
1996; Keller et al., 1998). Interestingly, the apoptosis res-
cue screen in which the PS2 ALG3 fragment was isolated
(see introduction) yielded another cDNA named ALG2,
which caused antisense inhibition of a calcium-binding
protein (Vito et al., 1996). However, when ALG2 was ex-
pressed in the sense orientation, this calcium-binding pro-
tein induced apoptosis (Lacana et al., 1997). It could be ar-
gued that coexpression of any calcium-binding protein
with presenilins would cause increased cell death. This is
clearly not the case as overexpression of another calcium-
binding protein, calbindin D28k, suppressed the proapop-
totic functions of PS (Guo et al., 1998). An imbalance in
calcium regulation could be catastrophic to the cell due to
the central role calcium plays in cellular processes includ-
ing its participation in the induction phase of apoptosis
(reviewed by McConkey and Orrenius, 1997).
Although there is some disagreement as to whether AD
involves a perturbation of calcium regulation (see Etche-
berrigaray et al., 1998), the consensus of research (opin-
ion) is indicative of such a defect. The uncertainty is in
part complicated by lack of reliable and easy methods to
measure intracellular calcium, let alone compare them in
different individuals. Nevertheless, numerous studies have
shown that calcium levels are altered in cells cultured from
AD patients, especially those harboring (or transfected
with) presenilin genes containing FAD-linked mutations
(Ito et al., 1994; Gibson et al., 1997; Mattson et al., 1998).
In summary, our results suggest that calmyrin, a cal-
cium-binding myristoylated protein, may play dynamic
and diverse roles in intracellular signaling, and we propose
that it is important in the modulation of presenilin func-
tion. Understanding the complex interplay between cal-
cium regulation, apoptotic signaling, and protein–protein
interactions will no doubt aid in deciphering the mecha-
nisms through which the presenilins function which in turn
could provide insight into the pathogenesis of Alzheimer’s
disease.
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